Harley-Davidson Inc vs Zimmer Biomet Holdings Inc — how do they compare? Harley-Davidson Inc trades at $27.42 (market cap $2.72B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.9× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| HOG | ZBH | |
|---|---|---|
Market Cap | $2.72B | $18.65B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $107.71 |
52-Week Low | $17.19 | $79.58 |
Enterprise Value | $3.13B | $25.72B |
Dividend Yield | 2.82% | 0.98% |
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.01, up 1.21% daily, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 EPS of $0.75, beating estimates, and raised full-year guidance. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin at 4.78%. Valuation ratios appear attractive with a P/E of 14.45 and P/B of 0.87. Recent news highlights North American sales strength and a strategic shift to U.S. production.
The outlook is cautiously optimistic; earnings beat and raised guidance support upside, but declining revenue and margin pressures pose risks. Analyst consensus is mixed with a $26 price target. Key risks include competitive threats and raw material costs. The stock's valuation discount offers potential if turnaround efforts gain traction.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Trailing returns across standard periods
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →